24 results
Thumbnail

D1.172 - Parallel Trajectories of Lung Function and Allergic Sensitization in Childhood Asthma: A 7-Year Prospective Study

Thumbnail

D1.180 - Hidden fragility behind optimal ACT score: identifying silent-risk phenotypes through clinical-biological dissociation

Thumbnail

D1.182 - Relationship between eHealth Literacy and Medication Adherence in Patients with Asthma: The Mediating Role of Self-Efficacy

Thumbnail

D1.171 - Real-World Exacerbation Outcomes After AIR Therapy Rescue Implementation: Toward a SABA-Free Era

Thumbnail

D1.173 - Sputum Tryptase Identifies Airway Mast Cell Activation Across Asthma Phenotypes

Thumbnail

D1.174 - Framing ADAM17 alterations across bronchial, sputum and nasal sites in asthma and controls

Thumbnail

D1.175 - Clinical Phenotypes of Difficult-to-treat and Mild Asthma Defined by Cluster Analysis

Thumbnail

D1.176 - Prognostic Evaluation of the Allergic March in Patients with Atopic Dermatitis

Thumbnail

D1.177 - Turkish Validity and Reliability of the Medication Adherence Report Scale for Asthma (MARS-A) in Adolescents with Asthma

Thumbnail

D1.178 - Real-World Comparison of Inhaled Corticosteroid Monotherapy versus Fixed-Dose Inhaled Corticosteroid–Long-Acting Beta-2 Agonist Combinations in Children Aged 6–11 Years with Persistent Asthma

Thumbnail

D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma

Thumbnail

D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report

Thumbnail

D1.108 - Optimization of phenotyping in severe T2-bronchial asthma

Thumbnail

D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy

Thumbnail

D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients

Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study

Thumbnail

D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study

Thumbnail

D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study

Thumbnail

D1.114 - Efficacy of Radical Endoscopic Surgery Combined with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps Complicated with Bronchial Asthma: A Real-World research

Thumbnail

D1.115 - Real World Assessment of Uncontrolled Severe Asthma in Canada - A Multi-Site Qualitative Survey of Type 2 Inflammatory Biomarkers and Clinical Outcomes